Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fovinaciclib - Chongqing Fochon Pharmaceutical

Next Previous
Drug Profile

Fovinaciclib - Chongqing Fochon Pharmaceutical

Alternative Names: FCN 437; FCN-437c; Fotonin; Fulvestaciclib; FUTUONING; HLX-902

Latest Information Update: 01 Oct 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chongqing Fochon Pharmaceutical
  • Developer Ahon Pharmaceutical; Chongqing Fochon Pharmaceutical; Shanghai Fosun Pharmaceutical
  • Class 2 ring heterocyclic compounds; Amides; Amines; Antineoplastics; Cyclopentanes; Piperazines; Piperidines; Pyridines; Pyrimidines; Small molecules; Thiophenes
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed HER2 negative breast cancer
  • No development reported Solid tumours

Most Recent Events

  • 01 Oct 2026 Registered for HER2-negative-breast-cancer (Combination therapy, First-line therapy, Late-stage disease) in China (PO), prior to October 2026 (Shanghai Fosun Pharmaceutical pipeline, October 2026)
  • 01 Oct 2026 Registered for HER2-negative-breast-cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in China (PO), prior to October 2026 (Shanghai Fosun Pharmaceutical pipeline, October 2026)
  • 21 Jul 2026 Shanghai Henlius Biotech plans a phase II trial for HER2-positive breast cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) (PO) in October 2026 (NCT07716046)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top